Eli Lilly and Company

Chugai Seiyaku Kabushiki Kaisha

Eli Lilly Company

David Michael Remick

Daniel Jon Sall

Qiang Yang

Satoshi Tsuchiya

Brian Stephen Muehl

Timothy Paul Burkholder

David Andrew Coates

Albert Kudzovi Amegadzie

Louis Nickolaus Jungheim

Cynthia Darshini Jesudason

David Mendel

Wolfgang Stenzel

Sajan Joseph

Takashi Emura

James Robert Henry

Russell Dean Stucky

Kenneth Allen Savin

Douglas P Kjell

Erik James Hembre, Ii

Yu Lu

Joshua Ryan Clayton

Kevin Matthew Gardinier

John Arnold Werner

Miles Goodman Siegel

Johnathan Alexander McLean

Gerd Ruehter

Xinchao Chen

Scott Alan Frank

David Anthony Barda

David Michael Bender

Yan Hao

Michael Alan Robertson

Boyu Zhong

Radhe Krishan Vaid

Adam Jan Sanderson

Simon James Richards

Rushad Eruch Karanjawala

Britta Evers

Jian Eric Hong

Nicholas Andrew Magnus

Steven Wayne Pedersen

Carlos Montero

Mark Steven Kerr

Kevin Paul Cole

Mark Edward Rempala

John Monte Knobeloch

Manabu Wadamoto

Minoru Yamawaki

Fumiki Kawagishi

Ashlee Jeanette Davis

Audrey Grace Mack

Ayman D Allian

Kenneth Derek Berglund

Derek Robert Starkey

Adriana Jemison

Xavier A Ortiz-medina

Molly Hess

Boris Arnoldovich Czeskis

Mai Khanh Nguyen Hawk

Alonso Jose Arguelles Delgado

Bharvin Kumar Rameschandra Patel

Yipin Yadav

Zhao-Qing Wang

Perry Clark Heath

Vipin Yadav

Susana Maria Garcia-Cerrada

Erik James Hembre

Mark Andrew Polizzi

The present invention relates to specific salts of (1S,5R)-(1α,5α,6α)-N-[1,1-dimethyl-2-[(3-methyl-2-pyridyl)oxy]ethyl]-3-azabicyclo[3.1.0]hexane-6-carboxamide, to pharmaceutical compositions comprising said salts, to methods of using said salts to treat physiological disorders, and to intermediates useful in the synthesis of the salts.

SSTR4 agonist salts

The present invention relates to the synthesis of 3-[(1S,2S)-1-[5-[(4S)-2,2-dimethyloxan-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl ]-4-methyl-6,7-dihydro-4H-pyrazolo [4,3-c] pyridine-5-carbonyl] indol-1-yl]-2-methylcyclopropyl]-4H-1,2,4-oxadiazol-5-one, or a salt thereof, and related synthetic intermediate compounds.

Process to make GLP1 RA and intermediates therefor

A novel salt of treprostinil and methods of its preparation and use are disclosed.

Treprostinil salt

Disclosed are methods of making selective estrogen receptor degraders (SERDs) of Formula A, as well as intermediates thereof, salts thereof including a pharmaceutically acceptable salt, and pharmaceutical compositions thereof: wherein either Ror Ris independently Cl, F, —CF, or —CH, and the other is H; and Ris H or PG.

Processes for the preparation of selective estrogen receptor degraders

The present invention relates to specific salts of (1S,5R)-(1&#x3b1;,5&#x3b1;,6&#x3b1;)-N-[1,1-dimethyl-2-[(3-methyl-2-pyridyl)oxy]ethyl]-3-azabicyclo[3.1.0]hexane-6-carboxamide, to pharmaceutical compositions comprising said salts, to methods of using said salts to treat physiological disorders, and to intermediates useful in the synthesis of the salts.

Provided herein are polymorphs of (2E)-3-fluoro-2-({[2-(4-methoxypiperidin-1-yl)pyrimidin-5-yl]oxy}methyl)prop-2-en-1-aminium 4-methylbenzenesulfonate, compositions thereof, methods of preparation thereof, and methods of use thereof.

Polymorphs of an SSAO inhibitor

The present invention provides novel CDK7 inhibitors and pharmaceutical compositions thereof: or a pharmaceutically acceptable salt thereof.

(E)-1-(4-(dimethylamino)but-2-enoyl)pyrrolidin-3-yl 4-((3-isopropyl-5-methylpyrazolo[1,5-a]pyrimidin-7-yl)amino)piperidine-1-carboxylate for inhibiting CDK7

The present invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof.

Selective BACE1 inhibitors

Abstract Compounds of a formula entitled, trans-4-[[(5S)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2-methyl-2H-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1H-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid, as a free acid or a pharmaceutically acceptable salt thereof, hydrate, and hydrate in crystalline form; pharmaceutical formulations; and methods of use are disclosed. 

[object Object]

The present invention relates to the gemcitabine prodrug 1-(2,2-difluoro-2-deoxy-&#x3b2;-D -ribofuranosyl)-4-(2-propyl-1-oxopentyl)aminopyrimidin-2-one useful as an oral drug for the treatment of cancer.

Amide prodrug of gemcitabine, compositions and use thereof

This application relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions thereof, and its use as an inhibitor of the NK-1 subtype of tachykinin receptors, as well as a process for its preparation and intermediates therefor. (I) wherein: D is a C-Calkane-diyl; Ris phenyl, which is optionally substituted with one to three substitutents independently selected from the group consisting of halo, C-Calkyl, C-Calkoxy, cyano, difluoromethyl, trifluoromethyl, and trifluoromethoxy; Ris a radical selected from the group consisting of: (IA), (IB), (IC), (ID), (IE), (IF), (IG), (IH) 

Triazole derivatives as tachykinin receptor antagonists

The present invention relates to a &bgr; adrenergic receptor agonist of formula (I) or a pharmaceutical salt thereof, which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type II diabetes and/or obesity. The compound can also be used to lower triglyceride levels and cholesterol levels or raise high density lipoprotein levels or to decrease gut motility. In addition, the compound can be used to reduced neurogenic inflammation or as an antidepressant agent. Compositions and methods for the use of the compounds in the treatment of diabetes and obesity and for lowering triglyceride levels and cholesterol levels or raising high density lipoprotein levels or for decreasing gut motility are also disclosed.

&bgr;3 adrenergic agonists

Growing community of inventors

Fishers, IN, United States of America

David Michael Remick